Ahold Delhaize Bought 988,000 Shares At €31.04
Ahold Delhaize repurchased 988,000 shares at €31.04 each, totaling €30.7 million, as part of a €1 billion buyback program.
Update: Railway Overhaul Promises Smoother Commutes for Queensland Travelers
VINCI's Seymour Whyte and John Holland JV awarded railway upgrade contract in Queensland, Australia.
Experian Cancela $10M En Deudas Para 5,000 Hispanos
Experian alivia $10M en deudas para 5,000 hispanos, mejorando acceso al crédito y educación financiera.
Experian Forgives $10M Debt For 5,000+ Hispanics
Experian is relieving $10 million in consumer debt for over 5,000 Hispanics to empower financial opportunities, offering free credit reports, educational resources, and…
Merck & Exelixis Test Zanzalintinib With Keytruda In Head/Neck Cancer, Welireg In Renal Cancer
Merck & Co., Inc. announced a collaboration with Exelixis to study Zanzalintinib with KEYTRUDA in head and neck cancer and with WELIREG in…
Stmicroelectronics Bought 364,100 Shares For EUR9.28M
STMicroelectronics repurchased 364,100 shares (0.04% of capital) for EUR 9.28M from Oct 7-11, 2024, under its share repurchase program for employee share options.
A1 Upgrades Aflenz Teleport To 400 Gbit/S, Improving Streaming, Broadcasting, Gaming
A1 Group upgraded international capacity from Aflenz to Frankfurt and Milan to 400 Gbit/s, enhancing streaming, broadcasting, and gaming services with low latencies.…
Finally! Digital Label-Free Eco-Friendly Package Return Service Available at DHL
DHL Group released a new press release about DHL Express launching a Label-Free Service for package returns globally, replacing traditional printing with a…
最新消息：中国批准 Enhertu 用于治疗 Her2 突变的转移性
Mon Oct 14 08:47:12 – 2024 UTC — 阿斯利康的Enhertu已在中国获得有条件批准，用于治疗HER2突变转移性非小细胞肺癌。 Enhertu是由第一三共公司发现的一种特异性HER2定向DXd抗体药物共轭物（ADC），由阿斯利康和第一三共公司联合开发和商业化。 Destiny-Breast12研究设计 Destiny-Breast12是一项开放标签、多中心、国际性IIIb/IV期研究，旨在评估T-DXd对Her2+乳腺癌患者（伴有或不伴有脑转移）的疗效和安全性。 患者在接受抗HER2治疗方案后病情反复进展，并在晚期最多接受过2次全身治疗。
Update: Enhertu Approved In China For Her2-Mutant Metastatic Nsclc
AstraZeneca's Enhertu has been conditionally approved in China as a therapy for HER2-mutant metastatic non-small cell lung cancer.